Avanos Medical

AVNS · NYSE

Price unavailable right now.

No price history for this range.

Key indicators

AVNS profitability and balance sheet ratios

EPS $0.1074 in Q1 FY26, down 23.8% on a year earlier.

EPS by quarter
PeriodEPS
Q2 FY24$0.0391
Q3 FY24$0.0915
Q4 FY24-$8.64
Q1 FY25$0.141
Q2 FY25-$1.66
Q3 FY25-$0.0302
Q4 FY25-$0.0281
Q1 FY26$0.1074

Where the money went

Q1 FY26, from revenue to net income

Avanos Medical brought in $182.2M of revenue in Q1 FY26, +8.8% on a year earlier. 3¢ of every dollar became profit.

Revenue
$182.2M
Costs, expenses and taxes
$177.1M
Net income
$5.1M
Net margin
2.8%

Income statement

Revenue and profit by reporting period

Revenue
Net income
AVNS income statement, quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26
Revenue$177.8M$180.9M$182.2M
Gross profit$86.0M$86.0M$94.2M
Operating income$0.1M$2.1M$8.9M
Net income−$1.4M−$1.3M$5.1M
Diluted EPS-$0.03-$0.03$0.11

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
AVNS balance sheet, quarterly
Line itemSep 2025Dec 2025Mar 2026
Total assets$1.1B$1.1B$1.1B
Total liabilities$0.3B$0.3B$0.3B
Shareholder equity$0.8B$0.8B$0.8B
Cash and short-term investments$0.1B$0.1B$0.1B
Total debt$0.1B$0.1B$0.1B

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
AVNS cash flow, quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26
Operating cash flow$14.0M$28.2M−$12.3M
Investing cash flow−$31.5M−$6.8M−$7.7M
Financing cash flow−$2.0M−$2.7M−$3.2M
Capital expenditure−$7.0M−$6.9M−$4.3M
Free cash flow$7.0M$21.3M−$16.6M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.